High-Throughput Screen for Inhibitors of Androgen Receptor-RUNX2 Transcriptional Regulation in Prostate Cancer.

about

High-Throughput Screen for Inhibitors of Androgen Receptor-RUNX2 Transcriptional Regulation in Prostate Cancer.

Item

http://www.wikidata.org/entity/Q38750494

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

High-Throughput Screen for Inh ...... Regulation in Prostate Cancer.

@en

type

Item

label

High-Throughput Screen for Inh ...... Regulation in Prostate Cancer.

@en

prefLabel

High-Throughput Screen for Inh ...... Regulation in Prostate Cancer.

@en

P1476

High-Throughput Screen for Inh ...... Regulation in Prostate Cancer.

@en

P2093

Baruch Frenkel

http://www.w3.org/2001/XMLSchema#string

Ben Y Tew

http://www.w3.org/2001/XMLSchema#string

Gillian H Little

http://www.w3.org/2001/XMLSchema#string

Jeremy O Jones

http://www.w3.org/2001/XMLSchema#string

Winston Vuong

http://www.w3.org/2001/XMLSchema#string

P2860

Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA

Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation

The RUNX genes: gain or loss of function in cancer

Regulation of adult bone turnover by sex steroids

Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG

Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts

Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.

Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity

Mutual transactivational repression of Runx2 and the androgen receptor by an impairment of their normal compartmentalization.

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.

P304

256-261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.116.234567

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27554677

http://www.w3.org/2001/XMLSchema#string